IL-4 receptor mutations

Current Opinion in Immunology

Volumn 11, Issue 6, 1999, Pages 615-620

  Pan, Ping Ying ^a   Rothman, Paul ^a  

^a Coll Phys S ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR;

ALLERGY; AMINO ACID SUBSTITUTION; APOPTOSIS; ASTHMA; DELETION MUTANT; GENE ACTIVATION; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; PROTEIN DOMAIN; REVIEW; SITE DIRECTED MUTAGENESIS;

EID: 0032705435     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00026-6     Document Type: Review

References (55)

1. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 17:1999;701-738. This reference is the most updated review on the IL-4 receptor and provides a comprehensive overview on IL-4 signaling mechanisms.
2. Chen H., Paul W.E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J Immunol. 159:1997;2240-2249.
3. Dubucquoi S., Desreumaux P., Janin A., Klein O., Goldman M., Tavernier J., Capron A., Capron M. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 179:1994;703-708.
4. Hsieh C.S., Heimberger A.B., Gold J.S. O'Garra, A., Murphy, K.M. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system Proc Natl Acad Sci USA. 89:1992;6065-6069.
5. Seder R.A., Paul W.E., Davis M.M., Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med. 176:1992;1091-1098.
6. Gascan H., Gauchat J.F., Roncarolo M.G., Yssel H., Spits H., de Vries J.E. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med. 173:1991;747-750.
7. Coffman R.L., Ohara J., Bond M.W., Carty J., Zlotnik A., Paul W.E. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol. 136:1986;4538-4541.
8. Vitetta E.S., Ohara J., Myers C.D., Layton J.E., Krammer P.H., Paul W.E. Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med. 162:1985;1726-1731.
9. Defrance T., Aubry J.P., Rousset F., Vanbervliet B., Bonnefoy J.Y., Arai N., Takebe Y., Yokota T., Lee F., Arai K.et al. Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes. J Exp Med. 165:1987;1459-1467.
10. Noelle R., Krammer P.H., Ohara J., Uhr J.W., Vitetta E.S. Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci USA. 81:1984;6149-6153.
11. Ohara J., Paul W.E. Up-regulation of interleukin 4/B-cell stimulatory factor 1 receptor expression. Proc Natl Acad Sci USA. 85:1988;8221-8225.
12. Thornhill M.H., Wellicome S.M., Mahiouz D.L., Lanchbury J.S., Kyan-Aung U., Haskard D.O. Tumor necrosis factor combines with IL4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol. 146:1991;592-598.
13. Bennett B.L., Cruz R., Lacson R.G., Manning A.M. Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E- selectin gene transcription is mediated by STAT6 antagonism of NF-kappaB. J Biol Chem. 272:1997;10212-10219.
14. Ohara J., Paul W.E. Receptors for B cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature. 325:1987;537-540.
15. Lowenthal J.W., Castle B.E., Christiansen J., Schreurs J., Rennick D., Arai N., Hoy P., Takebe Y., Howard M. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. J Immunol. 140:1988;456-464.
16. Murata T., Taguchi J., Puri R.K. Interleukin-13 receptor alpha′ but not alpha chain: a functional component of interleukin-4 receptors. Blood. 91:1998;3884-3891.
17. Obiri N.I., Debinski W., Leonard W.J., Puri R.K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 270:1995;8797-8804.
18. Obiri N.I., Leland P., Murata T., Debinski W., Puri R.K. The IL13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol. 158:1997;756-764.
19. Miloux B., Laurent P., Bonnin O., Lupker J., Caput D., Vita N., Ferrara P. Cloning of the human IL13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett. 401:1997;163-166.
20. •].
21. •] demonstrated the critical role for IL-13 in the manifestation of allergic asthma in the murine models. These studies showed that blockade of IL-13 by a soluble form of the IL-13 receptor (sIL-13Rα2-Fc fusion protein) reversed/ameliorated allergen-induced airway hyper-responsiveness and that administration of IL-13 induced the pathophysiological characteristics of asthma, independent of IgE and eosinophils but dependent on IL-4Rα
22. Donaldson D.D., Whitters M.J., Fitz L.J., Neben T.Y., Finnerty H., Henderson S.L., O'Hara R.M. Jr., Beier D.R., Turner K.J., Wood C.R.et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol. 161:1998;2317-2324.
23. Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu Rev Immunol. 16:1998;293-322.
24. Miyazaki T., Kawahara A., Fujii H., Nakagawa Y., Minami Y., Liu Z.J., Oishi I., Silvennoinen O., Witthuhn B.A., Ihle J.N.et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science. 266:1994;1045-1047.
25. Witthuhn B.A., Silvennoinen O., Miura O., Lai K.S., Cwik C., Liu E.T., Ihle J.N. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 370:1994;153-157.
26. Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., Ortaldo J.R., McVicar D.W., O'Shea J.J. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 370:1994;151-153.
27. Murata T., Noguchi P.D., Puri R.K. IL13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol. 156:1996;2972-2978.
28. Wang L.M., Keegan A.D., Paul W.E., Heidaran M.A., Gutkind J.S., Pierce J.H. IL-4 activates a distinct signal transduction cascade from IL-3 in factor-dependent myeloid cells. EMBO J. 11:1992;4899-4908.
29. Wang L.M., Keegan A.D., Li W., Lienhard G.E., Pacini S., Gutkind J.S., Myers M.G. Jr., Sun X.J., White M.F., Aaronson S.A.et al. Common elements in interleukin 4 and insulin signaling pathways in factor-dependent hematopoietic cells. Proc Natl Acad Sci USA. 90:1993;4032-4036.
30. Wang L.M., Myers M.G. Jr., Sun X.J., Aaronson S.A., White M., Pierce J.H. IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science. 261:1993;1591-1594.
31. Sun X.J., Wang L.M., Zhang Y., Yenush L., Myers M.G. Jr., Glasheen E., Lane W.S., Pierce J.H., White M.F. Role of IRS-2 in insulin and cytokine signalling. Nature. 377:1995;173-177.
32. Keegan A.D., Zamorano J. Regulation of gene expression, growth, and cell survival by IL-4: contribution of multiple signaling pathways. Cell Res. 8:1998;1-13.
33. Pernis A., Witthuhn B., Keegan A.D., Nelms K., Garfein E., Ihle J.N., Paul W.E., Pierce J.H., Rothman P. Interleukin 4 signals through two related pathways. Proc Natl Acad Sci USA. 92:1995;7971-7975.
34. Zamorano J., Wang H.Y., Wang L.M., Pierce J.H., Keegan A.D. IL4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J Immunol. 157:1996;4926-4934.
35. Zamorano J., Keegan A.D. Regulation of apoptosis by tyrosine containing domains of IL-4R alpha: Y497 and Y713, but not the STAT6-docking tyrosines, signal protection from apoptosis. J Immunol. 161:1998;859-867. This report implicated the carboxy-terminal domain (containing Tyr713) in the anti-apoptotic signaling pathway. Interestingly, the Tyr713→Phe mutation in the context of IL-4Rα had no effect on the protection from apoptosis mediated by IL-4. The effect could only be observed in the IL-2Rβ-IL-4Rα chimeric receptor.
36. dok and is bound by the amino-terminal SH2 domain of RasGAP.
37. Carpino N., Wisniewski D., Strife A., Marshak D., Kobayashi R., Stillman B., Clarkson B. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell. 88:1997;197-204.
38. Meier H., Myers D.D., Huebner R.J. Genetic control by the hr-locus of susceptibility and resistance to leukemia. Proc Natl Acad Sci USA. 63:1969;759-766.
39. Wang H.Y., Paul W.E., Keegan A.D. IL4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. Immunity. 4:1996;113-121.
40. Ryan J.J., McReynolds L.J., Keegan A., Wang L.H., Garfein E., Rothman P., Nelms K., Paul W.E. Growth and gene expression are predominantly controlled by distinct regions of the human IL4 receptor. Immunity. 4:1996;123-132.
41. Daeron M. Building up the family of ITIM bearing negative coreceptors. Immunol Lett. 54:1996;73-76.
42. Unkeless J.C., Jin J. Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol. 9:1997;338-343.
43. D'Ambrosio D., Hippen K.L., Minskoff S.A., Mellman I., Pani G., Siminovitch K.A., Cambier J.C. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science. 268:1995;293-297.
44. Burshtyn D.N., Scharenberg A.M., Wagtmann N., Rajagopalan S., Berrada K., Yi T., Kinet J.P., Long E.O. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity. 4:1996;77-85.
45. Ono M., Bolland S., Tempst P., Ravetch J.V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature. 383:1996;263-266.
46. Osborne M.A., Zenner G., Lubinus M., Zhang X., Songyang Z., Cantley L.C., Majerus P., Burn P., Kochan J.P. The inositol 5′-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation. J Biol Chem. 271:1996;29271-29278.
47. Marengere L.E., Waterhouse P., Duncan G.S., Mittrucker H.W., Feng F.S., Mak T.W. Regulation of T cell receptor signaling by tyrosine phosphatase SYP and association with CTLA-4. Science. 272:1996;1170-1173.
48. Hershey G.K., Friedrich M.F., Esswein L.A., Thomas M.L., Chatila T.A. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 337:1997;1720-1725.
49. Wang H.Y., Shelburne C.P., Zamorano J., Kelly A.E., Ryan J.J., Keegan A.D. Cutting edge: effects of an allergy-associated mutation in the human IL-4R alpha (Q576R) on human IL-4-induced signal transduction. J Immunol. 162:1999;4385-4389. This is a follow-up study of reference [48] by a different group. In this study, the mutant (Gln576→Arg) human IL-4Rα gene was stably expressed in a murine myeloid progenitor cell line 32D and in a mouse lymphoma cell line M12.4.1. However the responses generated from the mutant gene were similar to those of the wild-type receptor, implicating that additional alterations in the IL-4 signaling pathway were required for the observed phenotype in cells isolated from Gln576→Arg homozygotes.
50. ••], they found that the Gln576→Arg human IL-4Rα chain did not cause any significance difference in Stat6 activation, germline Iε transcription and proliferation mediated by IL-4 in a mouse pro-B cell line (Ba/F3).
51. Mitsuyasu H., Izuhara K., Mao X.Q., Gao P.S., Arinobu Y., Enomoto T., Kawai M., Sasaki S., Dake Y., Hamasaki N.et al. Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet. 19:1998;119-120. This group reported an Ile50 variant of IL-4Rα that associated with atopic asthma. Although the mutation did not significantly affect ligand-binding affinity, human and murine B lymphocyte cell lines expressing the Ile50 variant exhibited higher levels of cell growth, Iε promoter activation and Stat6 activation in response to IL-4 stimulation.
52. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A.et al. A family of cytokine-inducible inhibitors of signalling. Nature. 387:1997;917-921.
53. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Tada T., Yoshizaki K.et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:1997;924-929.
54. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:1997;921-924.
55. Losman J.A., Chen X.P., Hilton D., Rothman P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol. 162:1999;3770-3774. This report implicates SOCS-1 in the negative regulation of IL-4 signal transduction. The expression of SOCS-1 but not SOCS-2 was able to inhibit IL-4-induced activation of a Stat6 reporter in transient transfection. Stable cell lines expressing SOCS-1 showed decreased levels of Jak-1 and Stat6 activation.